



Commonwealth Edison

One First National Plaza, Chicago, Illinois
Address Reply to: Post Office Box 767
Chicago, Illinois 60690 - 0767

April 22, 1988

PRIORITY ROUTING	
First	Second
RA	RC
DBA	EDC
D	EDG
P	EDH
U	EDL
S	EDM
T	EDN
FILE	PER

objt 1 ✓

Mr. A. Bert Davis
Regional Administrator
U.S. Nuclear Regulatory Commission
Region III
799 Roosevelt Road
Glen Ellyn, IL 60137

Subject: Quad Cities Station Units 1 and 2
Transmittal of Information Pertaining
to LER 87-025-Control Room Habitability
NRC Docket Nos. 50-254 and 50-265

Dear Mr. Davis:

In a response to a request made by C. Gill of your staff, attached please find a copy of a safety significance evaluation performed by NUS Corporation. This evaluation was performed at the request of Commonwealth Edison in response to the above referenced LER.

The evaluation was performed in order to determine if the Control Room Operator Dose would have been below the General Design Criterion (GDC) 19 limit had a Design Basis Accident (DBA) occurred when the Standby Gas Treatment System (SBGTS) efficiency was lower than that used in previous radiological analyses. The radiological analyses were based on a 99% SBGTS charcoal efficiency whereas the existing Quad Cities Technical Specifications allow the SBGTS efficiency to be 90%.

Quad Cities Station personnel reviewed previous charcoal efficiency test results which showed that the efficiency was generally above 99%. However, at one time the test results showed a efficiency of 92.871%. The safety significance evaluation determined what the effect would be if a DBA had occurred at the time that the charcoal efficiency was at this level.

The analysis performed used a containment leakage rate of 1% per day of which 0.15% per day leakage is allowed through the Main Steam Line Isolation Valves (MSIV). Plant personnel have reviewed the results of past containment leak rate tests and have determined that the highest leakage rate as determined from the previous outage was 0.45% per day of which 0.062% per day leakage occurred via the MSIVs. The 30-day control room thyroid dose (had a DBA occurred at this time) would have been 16.3 rem using the actual containment leakage rates and the lower SBGTS efficiency (91.871% was conservatively used in this analysis to allow for a 1% bypass penetration of the charcoal trays).

BB05040206 BB0422
PDR ADDCK 05000254
PDR

5EO4
APR 25 1988

A.B. Davis

- 2 -

April 22, 1988


A second, and even more conservative calculation was done to verify that degradation of the leak tightness of the containment, between tests, would not have resulted in doses above the GDC limit. The analysis was also performed using a margin of 0.25% per day which was added to the actual containment leakage rate. This margin was utilized since it represents the same margin as presently allowed by the Quad Cities Technical Specifications when performing periodic testing. The acceptance criteria in the Technical Specification is 75% of the leak rate or 0.75% per day. With a margin of 0.25% per day (0.70% per day total leak rate of which 31.5 SCFH at 24 psig leaks through the MSIVs), the control room 30-day thyroid dose is still below the GDC-19 limit. In this case, the value calculated was 25.3 rem.

The methodology employed in the safety significance evaluation was presented to Mr. C. Gill in an April 12, 1988 conference call. Attached for the independent review of your staff, is a copy of the two calculations that were performed as well as curves which show operator doses as a function of SBGTS efficiency.

In consideration of the actual containment leakage rate, the control room operator doses would not have exceeded the GDC-19 limits had a design basis accident occurred when the SBGTS efficiency was 92.871%. Moreover, when an additional safety factor is included in the calculation for reasons of conservatism, the conclusions remain unchanged.

Please direct any questions you may have regarding this matter to this office.

Very truly yours,



I. M. Johnson
Nuclear Licensing Administrator

lm

cc: Quad Cities Resident Inspector (w/o Att.)

4510K

ENGINEERING CALCULATION

CLIENT/PROJECT CECO / HVAC UPGRADE CONTROL ROOM CALC. NO. 0570-M-03 REV. D

TITLE QUAD CITIES, CONTROL ROOM DOSE ANALYSIS,
LER SUPPORT (SAFETY SIGNIFICANCE OF LER)

AUTHOR/DATE	VERIFIED BY/DATE	APPROVED BY/DATE
<u>D. Shultz 4/1/88</u>	<u>ReBeleni 4/13/88</u>	<u>MR. M. Chiarlo 4-14-88</u>

PURPOSE:

THE OBJECTIVE OF THIS ANALYSIS IS TO DETERMINE IF THE CONTROL ROOM 30-DAY THYROID DOSE WOULD HAVE BEEN LESS THAN THE GDC-19 LIMITS HAD A DESIGN BASIS ACCIDENT OCCURRED WHEN THE SCTS EFF. WAS LOWER THAN THE VALUE USED IN THE RADIOPHYSICAL ANALYSIS (99%).

RESULTS:

AS DISCUSSED ON PG. 1, THE O.R. DOSES WILL BE CALCULATED IN THIS ANALYSIS USING ACTUAL CONTAINMENT AND HSIV LEAKRATES.

USING THE 12/86 UNIT 2 "AS LEFT" LEAKRATES (SEE ATTACHED TELECON) WITH A MORAIN EQUAL TO THOSE APPLIED IN THE TECH. SPEC'S, THE 30-DAY CONTROL ROOM THYROID DOSE WOULD BE LESS THAN THE GDC-19 LIMIT WHEN USING THE LOWEST SCTS EFFICIENCY IDENTIFIED (92.87%). (SEE PLOT ON PG. 6)

SUPERCEDED BY REV. _____	QUALITY CLASS <input checked="" type="checkbox"/> SAFETY RELATED <input type="checkbox"/> NON-SR <input type="checkbox"/> OTHER _____	DISTRIBUTION <input checked="" type="checkbox"/> PROJECT (2 copies (max) <input type="checkbox"/> DCC <input type="checkbox"/> OTHER _____	VERIFICATION METHOD <input type="checkbox"/> REVIEW <input type="checkbox"/> ALT. ANALYSIS
SUPPLEMENTED BY CALC. NO. _____			

CLIENT: CELO	FILE NO.: 0476-M-03	BY: D. STODLET	PAGE 1 OF 9
SUBJECT: OC. DOSE ANALYSIS, LER SUPPORT		CHECKED BY: <i>[Signature]</i>	DATE: 4/13/88

1.0 OBJECTIVE

THE OBJECTIVE OF THIS ANALYSIS IS TO DETERMINE IF THE CONTROL ROOM 30-DAY THYROID DOSE WOULD HAVE BEEN LESS THAN THE GDC-19 LIMITS HAD A DESIGN BASIS ACCIDENT (LOCA) OCCURRED WHEN THE SGTS CHARGE EFFICIENCY WAS LOWER THAN WHAT WAS USED IN THE PREVIOUS RADIOPHYSICAL ANALYSIS (99%).

THE SGTS EFFIL. WAS BELOW 99% BETWEEN 3/87 AND 11/87 AT WHICH TIME THE OPERATING PROCEDURES REQUIRED THE C.R. TO BE PLACED IN THE FILTERED PRESSURIZATION MODE WITHIN 8 HOURS OF THE ACCIDENT.

2.0 APPROACH

INSPECTION OF CURVE IN CALC. 5467-M-012 SHOWS THAT THE C.R. DOSE EXCEEDS THE GDC-19 LIMIT BY \approx 5.0 REM WITH A SGTS EFFICIENCY OF 92% AND THE C.R. PRESSURIZED AT 8 hrs., HOWEVER THE RESULTING OPERATOR DOSES MAY HAVE BEEN BELOW ^{THE GDC-19 LIMITS} DUE TO SOME OF THE COMPONENTS THAT EFFECT THE DOSE BEING BELOW THE VALUE USED IN THE ANALYSIS. ONE SUCH PARAMETER IN WHICH TEST RESULTS ARE AVAILABLE IS THE CONTAINMENT OF MSIV LEAKAGES. THE ATTACHED TELECON SHOWS THE TEST RESULTS OR "AS LEFT" CONDITION AT THE OUTAGE PRIOR TO THE PERIOD IN WHICH THE CHARGE WAS DISCARDED.

CLIENT: CECO	FILE NO.: 0376-M-03	BY: D. STUDLEY	PAGE 2 OF 9
SUBJECT: QC. CR Dose Analysis, LER Support		CHECKED BY: <i>REB</i>	DATE: 4/13/83

3.0 REFERENCES

- 3.1 NUS CALC. 5404-M-07/51 "QUOD CITIES CONTROL ROOM DOSE ANALYSIS", SUPPLEMENT TO 5404-M-07, DATED 10/5/87.
- 3.2 ORNL - NSIC S "U.S. CONTAINMENT TECHNOLOGIES", ORK RIDGE NATIONAL LAB AND BELCHER CORP., AUG. 1965.
- 3.3 TELECON BETWEEN BOB CASTRO OF QC TECH STAFF AND D. STUDLEY NUS (ATTACHED)
- 3.4 NUS CALC. 5404-M-02 "QUOD CITIES INFILTRATION ANALYSIS", DATED 4/17/87.
- 3.5 NUS CALC. 5404-M-012 "QUOD CITIES, CONTROL ROOM DOSE ANALYSIS, PLOT OF DOSE AS A FUNCTION OF SHIPS EFF." DATED 1/11/88 (PLW 21126450, pg 4)
- 3.6 NUS CALC. 0376-M-02 "QUOD CITIES CONTROL ROOM TECHNOLOGY DUE" DATED 3/11/88.
- 3.7 Q.C. TECHNICAL SPECIFICATION, DPR-29 "3.7 / 4.7 CONTAINMENT SYSTEMS".

4.0 ASSUMPTIONS

THE ASSUMPTIONS USED IN THIS ANALYSIS ARE THE SAME AS IN THE CALC. 5404-M-07/51

CLIENT: CELO	FILE NO.: 0476-M-03	BY: D. STUDER	PAGE 3 OF 9
SUBJECT: LRC. C.R. DOSE ANALYSIS		CHECKED BY: <i>[Signature]</i>	DATE: 4/3/83

S.D. ANALYSIS

PER THE ATTACHED TELECON, THE UNIT 2 TOTAL INTEGRATED LEAKRATE WAS LEFT AT < 0.4% WT % / DAY IN LIEU OF THE TECRA SPEC. VALUE OF 1.0 WT. % / DAY WHICH WAS USED IN THE ANALYSIS TO DEVELOP THE ATTACHED PLOT.

PER THE ATTACHED TELECON, THE UNIT 2 HSIV LEAKAGE CONTRIBUTION AS LEFT WAS < 20 CFH @ 24 PSIG FOR THE SUM OF ALL FOUR HSIV'S IN LIEU OF 46 CFH (11.5 % VALUE) WHICH WAS USED IN THE ANALYSIS TO DEVELOP THE ATTACHED CURVE.

THE DOSES WILL BE CALCULATED USING A 90% EFF OF 91.871 % (92.871 % FROM THE ATTACHED TELECON LESS 1% BYPASS)

THE DOSE CONTRIBUTION FROM BOTH THE HSIV LEAKAGE AND STOCK RELEASES ARE LINEAR WITH LEAKRATE AND WILL RESULT IN A ZERO DOSE @ ZERO LEAKRATE - THIS CAN BE SHOWN BY REVIEWING THE DOSE ANALYSIS EQUATIONS IN THE USER MANUAL FOR THE "AXIDENT" PROGRAM AND CAN BE VERIFIED BY REVIEWING THE RESULTS IN NUD'S CALCULATIONS 5464-M-07/51 AND 0476-H-02.

THE HSIV LEAKRATE WILL BE EXTRAPOLATED TO THE DESIGN BASIS PRESSURE OF 40 PSIA USING THE LAMINAR (VISCOUS) FLOW EXTRAPOLATION FACTOR IN ORNL HSIC-5 (SEE CDR 5464-M-07/51 , PG. B)

$$\frac{L_1}{L_2} = \frac{62.7 - 1/62.7}{39.9 - 1/39.9} = 1.55$$

CLIENT: CELO	FILE NO.: 0 876 - M - 03	BY: D. STUDLET	PAGE 4 OF 9
SUBJECT: QC. CONTROL RM DOSE ANALYSIS		CHECKED BY: <i>[Signature]</i>	DATE: 4/13/88

5.0 ANALYSIS (CONT.)

1. THE TOTAL HSIV LEAKAGE

$$= 1.58 \text{ (20 CFH)} = 31.6 \text{ SCFH}$$

THE %/DAY THROUGH THE HSIV'S @ 48 PSIG =

$$\left(\frac{14.7 \text{ psig}}{62.7 \text{ psig}} \right) \left(\frac{31.6 \text{ SCF}}{\text{hr}} \right) \left(\frac{24 \text{ hr}}{\text{day}} \right) \left(\frac{1}{286,234 \text{ CF}} \right) \times 100$$

$$= 0.062 \% \text{/day}$$

A MARGIN SHOULD BE ADDED TO THE LEAKRATES TO ALLOW FOR THE DEGRADATION OF THE SEALS BETWEEN TESTING. THE Q.C. TECH. SPEC. LIMITS THE TOTAL INTEGRATED LEAKRATE AND HSIV LEAKRATE TO 75% OF THE TEST SPEC VALUE. THE ANALYSIS WILL CONSERVATIVELY ADD THE ABSOLUTE VALUE OF THE MARGIN TO THE TEST RESULTS FOR THE POSSIBILITY OF DEGRADATION OF THE SEALS AFTER THE LEAK TEST.

$$\text{TOTAL INTEGRATED TECH. SPEC VALUE} = 1\% \text{/day}$$

$$\therefore \text{MARGIN} = 0.25 \% \text{/day}$$

$$\text{HSIV TECH. SPEC. VALUE} = 1.58 \text{ (6 CFH)} = 72.6 \text{ SCFH}$$

$$\therefore \text{MARGIN} = 18.17 \text{ SCFH}$$

$$\therefore \text{REVISED HSIV LEAKAGE w/MARGIN} = 31.6 + 18.17 = 49.77 \text{ SCFH}$$

$$\% \text{/day} = \left(\frac{14.7 \text{ psig}}{62.7 \text{ psig}} \right) \left(\frac{49.77 \text{ SCF}}{\text{hr}} \right) \left(\frac{24 \text{ hr}}{\text{day}} \right) \left(\frac{1}{286,234 \text{ CF}} \right) \times 100 = 0.0978 \% \text{/day}$$

$$\text{LEAKAGE THROUGH STACK w/MARGIN} = 0.45 + 0.25 = 0.602 \text{ SCFH}$$

$$= 0.602 \% \text{/day}$$

CLIENT: CECIS	FILE NO.: 0370-M-03	BY: D. STUDER	PAGES OF 9
SUBJECT: QC. CONTROL RH DOSE ANALYSIS		CHECKED BY: <i>M. S.</i>	DATE: 4/3/58

S.O. ANALYSIS

THE DOSE CONTRIBUTION FROM EACH LEAKAGE PATH
WILL BE CALCULATED AT 99% AND 90% SATS
EFFICIENCY

* 30 DAY THYROID DOSE w/ 99% SATS EFF. (w/ H2OGEN)

0.602 % / DAY LEAKAGE TO SECONDARY

0.098 % / DAY MSIV LEAKAGE

260 CPM INFIL

8 HR PRESSURE SWELLING / FILTRATION

Some ISOLATION

STOCK DOSE (SEE CEC. 5061-m-07/SI, PG 13)

$$= 3.61 \text{ REM} \times 0.602/0.85 = 2.56 \text{ REM}$$

MSIV DOSE

$$= 7.03 \text{ REM} \times 0.098/0.15 = 4.59 \text{ REM}$$

$$\text{TOTAL} = 7.15 \text{ REM}$$

* 30 DAY THYROID DOSE w/ 90% SATS EFF. (w/ H2OGEN)STOCK DOSE

$$= 36.1 \text{ REM} \times 0.602/0.85 = 25.6 \text{ REM}$$

MSIV DOSE

$$= 7.03 \text{ REM} \times 0.098/0.15 = 4.59 \text{ REM}$$

30.2 REM

THE PLOT OF THE 30-DAY THYROID DOSE IS SHOWN
ON PG 7.

CLIENT: CELO	FILE NO.: 0976-M-03	BY: D. STUDLEY	PAGE 6 OF 9
SUBJECT: QC Control Room Dose Analysis		CHECKED BY: <i>RBS</i>	DATE: 4/13/88

S. O ANALYSIS (CONT)

IN ADDITION, THE 30-DAY CONTROL ROOM THYROID DOSE WILL BE CALCULATED USING THE TEST RESULTS W/O THE MARGIN.

$$\begin{aligned} \text{SO STOCK LEAKAGE} &= 0.45 - 0.062 = 0.388 \% / \text{DOY} \\ \text{MSIV LEAKAGE} &= 0.062 \% / 0.24 \end{aligned}$$

* 30 DAY THYROID DOSE w/ 99% SATS (AS TESTED)

STOCK DOSE

$$= 3.61 \text{ REM} \times 0.388 / 0.85 = 1.65 \text{ REM}$$

MSIV DOSE

$$= 7.03 \text{ REM} \times 0.062 / 0.15 = \frac{2.91 \text{ REM}}{4.56 \text{ REM}}$$

* 30 DAY THYROID DOSE w/ 90% SATS (AS TESTED)

STOCK DOSE

$$= 36.1 \text{ REM} \times 0.388 / 0.85 = 16.5 \text{ REM}$$


MSIV DOSE

$$= 7.03 \text{ REM} \times 0.062 / 0.15 = \frac{2.91 \text{ REM}}{16.4 \text{ REM}}$$

NUS CORPORATION AND SUBSIDIARIES

STANDARD CALCULATION SHEET

CLIENT: CECO	FILE NO.: 0570-M-03	BY: D. ST. JAMES	PAGE 7 OF 9
SUBJECT: RC CONTROL RM DOSE LIMITS	CHECKED BY: <i>M. B.</i>	DATE: 4/5/89	



G.C. - 30-DAY CONTROL RM THYROID DOSE
 BASED ON A TOTAL INTEGRATED LEAKRATE
 OF 0.7% / DAY (0.45% / DAY FROM UNIT 2
 TEST ON 12/86 PLUS 0.25% / DAY MARGIN)
 OF WHICH 31.5 CFH @ 20PSIG THROUGH
 THE MSIV'S (20 CFH FROM UNIT 2 TEST
 ON 12/86 PLUS 11.5 CFH MARGIN)

NUS CORPORATION AND SUBSIDIARIES

TELECON NOTE

CONTROL NO	DATE	TIME
0576	4/8/88	4:50

DISTRIBUTION:

M. J. GIARRATANO
R. MUCHINSKY

BETWEEN	OF	PHONE
BOB CASTRO	G.C. TECH STAFF	X-2164 (309) 654-2241

AND:

DOVE STUDLEY

DISCUSSION:

BOB DEALLED WITH THE CONTAINMENT LEAKAGES AND

HSIV LEAKAGES FOR BOTH UNITS "AS LEFT" AFTER
THE PREVIOUS OUTAGE.

* UNIT 1 - OPERATED FROM 3/86 TO 9/87

AS LEFT AT END OF 3/86 OUTAGE = < 0.25 WT% / DAY

(THIS IS TOTAL INTEGRATED & INCLUDES HSIV'S, ETC)

HSIV LEAKAGE AS LEFT = < 7 CFH @ 24 PSIG FOR
TOTAL OF ALL FOUR VALVES

* UNIT 2 - OPERATED FROM 12/86 TO PRESENT

AS LEFT AT END OF 12/86 OUTAGE = < 0.45 WT% / DAY

HSIV LEAKAGE AS LEFT = < 20 CFH @ 24 PSIG FOR
TOTAL OF ALL FOUR VALVES

BOB STATED THAT THE LOWEST TEST RESULTS ON THE 304's

SHOWED A CHARGE EFF. OF 92.871%. (OTHER TESTS ON

THE SAME TRAYS SHOWED EFF.'S AS HIGH AS 99.983%)

ACTION ITEM:

NUS TO VERIFY FOR BOB THAT THE OPERATION DUSES
WOULD HAVE BEEN BELOW THE GOC-19 LIMITS HAD
A TEP OCCURRED WHEN THE CHARGE WAS AT A
DESIGNATED CONDITION, UTILIZING THE ABOVE TESTED PARAMETERS.

04740-M-03 pg. 9 of 9
BY: DRS
CCD: [Signature]

NUS CORPORATION AND SUBSIDIARIES

STANDARD CALCULATION
SHEET

CLIENT: CSCO	FILE NO.: 54640-M-012	BY: D.S-WOLLET	PAGE 4 OF 4
SUBJECT: G.C., C.R. DOSE ANALYSIS		CHECKED BY: <i>Glenn</i>	DATE: 1/8/88

